Abstract:Introduction: Metastasis of breast cancer to the bone is a common complication and occurs in 65-80% of late-stage patients. Specifically, the development of osteolytic bone lesions increases patient morbidity and mortality with debilitating skeletal complications. Mitophagy is a selective form of autophagy that removes damaged or excessive mitochondria in response to various metabolic stresses. However, the role of mitophagy in development of cancer remains largely unclear. The Janus-faced role of mitophagy during tumorigenesis leads to a novel challenge when targeting it for cancer therapies. This study focuses on the role of mitophagy deficiency in breast cancer osteolytic bone metastasis, and explores the potential of rescuing mitophagy deficiency as possible therapeutic targets for metastatic disease. Methods: Specific single-guide RNAs (sgRNAs) were used to deplete ULK1 expression in breast cancer cell lines. Mitophagy was monitored by detecting Tom20 and Hsp60. In addition, mitochondrial DNA (mtDNA) was used to further confirm the reduction of mitochondrial mass. For bone metastasis studies, luciferase-tagged tumor cells were injected into the left cardiac ventricle of anesthetized female nude mice. Metastatic progression was monitored by bioluminescence imaging (BLI). Micro-CT imaging was used to detect bone volume, cortical wall thickness, trabecular thickness and number in mice of tibia. TRAP assay was used to detect osteoclast differentiation assays. Results: We found that the core Atg protein ULK1 was not only expressed at low level in breast cancer, but also required for hypoxia-induced mitophagy. ULK1-related mitophagy deficiency promoted the formation of metastatic osteolytic lesions in experimental bone metastasis mouse model with MDA-MB-231 cells. TRAP staining revealed that mature osteoclasts significantly increased in RAW264.7 cells treated with CM from ULK1-knockout breast cancer cells. In addition, MEK inhibitor trametinib was sufficient to upregulate the expression of ULK1 and reduced the release of cytokines, which is key to osteoclast differentiation via triggering mitophagy, thereby effectively blocking breast cancer osteolytic bone metastasis. Conclusion: In conclusion, we demonstrate the functional importance of mitophagy defect in breast cancer for promoting osteolytic bone metastasis. We also provide strong preclinical evidence for using MEK-ERK pathway inhibitors to disrupt ERK kinase-involved ULK1 degradation and induce mitophagy as a breast cancer bone metastasis therapy. Citation Format: Rong Deng, Hai-Liang Zhang, Rui-Zhao Cai, Jun Tang, Xiao-Feng Zhu. Mitophagy deficiency promotes osteolytic bone metastasis in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 38.

BRCA1 Deficiency: BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis (Adv. Sci. 6/2020)

Brca1 Deficiency Induces Protective Autophagy To Mitigate Stress And Provides A Mechanism For Brca1 Haploinsufficiency In Tumorigenesis

Abstract 1397: Metabolic CRISPR-Cas9 screening identifies loss of mitochondria Gene M in triple-negative breast cancer to promote lung metastasis via immune modulation

Research Progress on Mitochondria Regulating Tumor Immunity.

Loss of Function of BRCA1 Promotes EMT in Mammary Tumors Through Activation of TGFβR2 Signaling Pathway

Abstract 38: Mitophagy Deficiency Promotes Osteolytic Bone Metastasis in Breast Cancer

Myeloid PTEN Loss Affects the Therapeutic Response by Promoting Stress Granule Assembly and Impairing Phagocytosis by Macrophages in Breast Cancer

BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.

Abstract 2685: Modulating Tumor Microenvironments Through Inflammasome and IL-1 Pathways

Mitophagy: insights into its signaling molecules, biological functions, and therapeutic potential in breast cancer

Mitophagy in tumor: foe or friend？

Abstract #4440: BRCA1 Modulates Malignant Cell Behavior, the Expression of Survivin and Chemosensitivity in Human Breast Cancer Cells

Tumor Suppressor BRCA1 Epigenetically Controls Oncogenic Microrna-155

Abstract B011: BRCA2 haploinsufficiency induces P53 degradation in primary mammary epithelial cells – a crucial early event in breast tumor promotion

BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway

MicroRNA-20a-mediated Loss of Autophagy Contributes to Breast Tumorigenesis by Promoting Genomic Damage and Instability

BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment that Promotes Metastasis and Immunotherapy Resistance

MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer

Data from Absence of the Full-Length Breast Cancer–Associated Gene-1 Leads to Increased Expression of Insulin-Like Growth Factor Signaling Axis Members

Mitophagy in tumorigenesis and metastasis

BRCA1 is an Essential Regulator of Heart Function and Survival Following Myocardial Infarction